Treatment of Advanced Melanoma With MK-3475 and Peginterferon
Status:
Completed
Trial end date:
2020-07-17
Target enrollment:
Participant gender:
Summary
This study is to test how safe it is to give the combination of PEG IFN-α2b (SYLATRON) and
MK-3475, an investigational drug, to patients with advanced melanoma. Its effectiveness
against melanoma will also be evaluated.
Phase:
Phase 1
Details
Lead Sponsor:
Hassane M. Zarour, MD
Collaborators:
Melanoma Research Alliance Merck Sharp & Dohme Corp.